ArticleAnnals of hematology2023

Rituximab versus obinutuzumab-based first-line chemoimmunotherapy for follicular lymphoma-a real-world multicenter retrospective cohort study.

Tamar Berger et al.PubMed ↗Publisher ↗

No numbers read from the abstract.